Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin

Results of a Southeastern cancer study group trial

J. D. Hainsworth, S. D. Williams, Lawrence Einhorn, R. Birch, F. A. Greco

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Between July 1979 and May 1982, we treated 45 male patients with refractory germinal neoplasms. All patients had previously received intensive cisplatin-containing combination chemotherapy regimens. Patients received salvage chemotherapy with VP-16 and cisplatin ± bleomycin ± doxorubicin. Of 44 evaluable patients, 19 (43%) achieved complete remissions with salvage chemotherapy, 12 (27%) had partial remissions, and nine (21%) had no response. Four patients (9%) were not evaluable for response due to early death or noncompliance but are considered treatment failures. Ten patients (23%) remain alive and continuously disease free 20 to 39 months (median, 29 months) after completion of therapy. Hematologic toxicity was severe, with one death related to sepsis. Bleomycin-induced pulmonary fibrosis occurred in 17 patients with two fatalities. The addition of bleomycin and/or doxorubicin to this regimen increases toxicity and probably does not improve treatment results. Salvage chemotherapy with VP-16 and cisplatin offers potentially curative therapy to men with resistant germinal tumors.

Original languageEnglish
Pages (from-to)666-671
Number of pages6
JournalJournal of Clinical Oncology
Volume3
Issue number5
StatePublished - 1985
Externally publishedYes

Fingerprint

Etoposide
Cisplatin
Bleomycin
Neoplasms
Drug Therapy
Doxorubicin
Therapeutics
Pulmonary Fibrosis
Combination Drug Therapy
Treatment Failure
Sepsis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin : Results of a Southeastern cancer study group trial. / Hainsworth, J. D.; Williams, S. D.; Einhorn, Lawrence; Birch, R.; Greco, F. A.

In: Journal of Clinical Oncology, Vol. 3, No. 5, 1985, p. 666-671.

Research output: Contribution to journalArticle

@article{cce28ac320fe4e07bc33b3c866535ee7,
title = "Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: Results of a Southeastern cancer study group trial",
abstract = "Between July 1979 and May 1982, we treated 45 male patients with refractory germinal neoplasms. All patients had previously received intensive cisplatin-containing combination chemotherapy regimens. Patients received salvage chemotherapy with VP-16 and cisplatin ± bleomycin ± doxorubicin. Of 44 evaluable patients, 19 (43{\%}) achieved complete remissions with salvage chemotherapy, 12 (27{\%}) had partial remissions, and nine (21{\%}) had no response. Four patients (9{\%}) were not evaluable for response due to early death or noncompliance but are considered treatment failures. Ten patients (23{\%}) remain alive and continuously disease free 20 to 39 months (median, 29 months) after completion of therapy. Hematologic toxicity was severe, with one death related to sepsis. Bleomycin-induced pulmonary fibrosis occurred in 17 patients with two fatalities. The addition of bleomycin and/or doxorubicin to this regimen increases toxicity and probably does not improve treatment results. Salvage chemotherapy with VP-16 and cisplatin offers potentially curative therapy to men with resistant germinal tumors.",
author = "Hainsworth, {J. D.} and Williams, {S. D.} and Lawrence Einhorn and R. Birch and Greco, {F. A.}",
year = "1985",
language = "English",
volume = "3",
pages = "666--671",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin

T2 - Results of a Southeastern cancer study group trial

AU - Hainsworth, J. D.

AU - Williams, S. D.

AU - Einhorn, Lawrence

AU - Birch, R.

AU - Greco, F. A.

PY - 1985

Y1 - 1985

N2 - Between July 1979 and May 1982, we treated 45 male patients with refractory germinal neoplasms. All patients had previously received intensive cisplatin-containing combination chemotherapy regimens. Patients received salvage chemotherapy with VP-16 and cisplatin ± bleomycin ± doxorubicin. Of 44 evaluable patients, 19 (43%) achieved complete remissions with salvage chemotherapy, 12 (27%) had partial remissions, and nine (21%) had no response. Four patients (9%) were not evaluable for response due to early death or noncompliance but are considered treatment failures. Ten patients (23%) remain alive and continuously disease free 20 to 39 months (median, 29 months) after completion of therapy. Hematologic toxicity was severe, with one death related to sepsis. Bleomycin-induced pulmonary fibrosis occurred in 17 patients with two fatalities. The addition of bleomycin and/or doxorubicin to this regimen increases toxicity and probably does not improve treatment results. Salvage chemotherapy with VP-16 and cisplatin offers potentially curative therapy to men with resistant germinal tumors.

AB - Between July 1979 and May 1982, we treated 45 male patients with refractory germinal neoplasms. All patients had previously received intensive cisplatin-containing combination chemotherapy regimens. Patients received salvage chemotherapy with VP-16 and cisplatin ± bleomycin ± doxorubicin. Of 44 evaluable patients, 19 (43%) achieved complete remissions with salvage chemotherapy, 12 (27%) had partial remissions, and nine (21%) had no response. Four patients (9%) were not evaluable for response due to early death or noncompliance but are considered treatment failures. Ten patients (23%) remain alive and continuously disease free 20 to 39 months (median, 29 months) after completion of therapy. Hematologic toxicity was severe, with one death related to sepsis. Bleomycin-induced pulmonary fibrosis occurred in 17 patients with two fatalities. The addition of bleomycin and/or doxorubicin to this regimen increases toxicity and probably does not improve treatment results. Salvage chemotherapy with VP-16 and cisplatin offers potentially curative therapy to men with resistant germinal tumors.

UR - http://www.scopus.com/inward/record.url?scp=0021905642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021905642&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 666

EP - 671

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -